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Abstract 
Background: Metabolic syndrome (MetS) is a cluster of risk factors for type 2 diabetes (Type2 DM) and cardiovascular 
diseases (CVD), and its prevalence varies based on region, population, and sex. Newborns of women with MetS have a 
greater risk of adverse perinatal outcomes. This study explores the prevalence of metabolic syndrome in non-diabetic, 
pregnant Angolan women and the adverse perinatal outcomes associated with it.
Methods: This cross-sectional study collected the demographic, anthropometric and clinical data of 675 pregnant 
women in the maternity ward of General Hospital in Huambo, Angola. Metabolic syndrome was defined using four 
criteria: the third report of the National Cholesterol Education Program Adult Treatment Panel (ATPIII), the Joint Interim 
Statement (JIS), and definitions by both Bartha et al. and Chatzi et al.
Results: The crude prevalence of metabolic syndrome was 36.6 % based on the JIS definition, 29.2 % based on NCEP 
ATPIII, 12.6 % based on Chatzi et al. and 1.8 % based on Bartha et al. In general, the prevalence of adverse perinatal 
outcomes was 14.1 %.
Conclusions: There was a high prevalence of metabolic syndrome, depending on the criteria used, and thus a great 
need to harmonize the criteria and cutoff points. Perinatal adverse outcomes were higher in pregnant women with 
metabolic syndrome.
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Background
Metabolic syndrome (MetS) is a cluster of risk factors 
for type 2 diabetes (Type2 DM) and cardiovascular dis-
eases (CVD), with insulin resistance (IR) proposed as the 
linking factor [1]. It includes dyslipidemia elevated tri-
glycerides and apolipoprotein B (apoB), containing lipo-
proteins and low high-density lipoproteins (HDL), as well 
as elevated arterial blood pressure (BP) and dysregulated 
glucose homeostasis. Abdominal obesity and/or IR have 
also gained increasing attention as important compo-
nents of the syndrome. Despite the many components 
and clinical implications of MetS, there are still no uni-
versally accepted pathogenic mechanisms or clearly 
defined diagnostic criteria [2], for the syndrome.
Over the past few decades, several definitions of MetS 
have been proposed using various diagnostic criteria: 
WHO  [3, 4], the National Cholesterol Education Pro-
gram Third Adult Treatment Panel (ATPIII)  [5], and 
more recently, the International Diabetes Federation 
(IDF) (2005). In an attempt to unify the criteria, in 2009, 
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Joint Interim Statement (JIS) by several organizations. 
Notwithstanding the various definitions, central obesity, 
dyslipidemia, hyperglycemia and elevated BP are the key 
characteristics of MetS [6].
In the same year as the JIS publication, a study con-
ducted in Brazil showed that the prevalence of MetS in 
pregnancy increases with the decline in glucose toler-
ance. The study also demonstrated that the glycemic 
profile is a useful diagnostic tool for identifying meta-
bolic abnormalities related to MetS in pregnancy and 
predicting the occurrence of adverse perinatal outcomes 
(APO). The authors concluded that MetS diagnosed dur-
ing mid-pregnancy is a predictor of APO, both in women 
with gestational diabetes (GDM) and in those with mild 
gestational hyperglycemia (MGH) who are not currently 
classified as having GDM. These results reinforced the 
importance of screening for the components of MetS to 
identify pregnant women who are at high risk for APO 
[7].
During the same period, research was published study-
ing different populations and showed an association 
between maternal MetS in early pregnancy and higher 
risk for both preterm birth [8] and GDM [9].
In 2008, Bartha et  al. modified the NCEP ATPIII for 
pregnancy, establishing a new cutoff for several param-
eters: pre-pregnancy BMI >30  kg/m2, plasma triglycer-
ides ≥2 SD for gestational age, HDL cholesterol >2 SD for 
gestational age, blood pressure ≥130/≥85  mm/Hg, and 
fasting glucose ≥110 mg/dl [10].
Recognition of MetS during pregnancy could help 
identify a subgroup of women who may not only develop 
a pregnancy-related condition but are also potentially at 
an increased risk for either metabolic or cardiovascular 
adverse conditions later in life.
Adverse outcome indexes were designed to measure 
the quality of perinatal care [11–13].
The clinical outcomes are a function of both the 
received healthcare and the basic health status of the 
patient [15].
In sub-Saharan Africa, many countries are experienc-
ing a rapid demographic and epidemiological transition 
[16].
Angola is a country in sub-Saharan Africa that has 
undergone significant political changes over the last sev-
eral years, accompanied by rapid economic growth and 
an increased urbanization rate. These changes may be 
implicated in the increasing prevalence of MetS caused 
by the rise in obesity due to insufficient physical activ-
ity, dyslipidemia, hypertension and hyperglycemia [16]. 
However, the prevalence of the MetS in pregnant Ango-
lan women, the specific factors contributing to its occur-
rence and its perinatal implications remain unknown. 
Despite the diversity of definitions, the prevalence of 
MetS is well known in several populations worldwide 
[2]. To date, however, no such information is available in 
communities in low- to mid-income countries, such as 
non-diabetic, pregnant Angolan women. There are also 
no studies on the association between APO and maternal 
MetS in pregnancy.
Our hypothesis is that in a country with a high preva-
lence of MetS, norm glycemic pregnant women may 
also exhibit a high prevalence of MetS, which has direct 
effects on the perinatal results. The detection of MetS 
during pregnancy has not been established in the litera-
ture, and it merits a comparison between different diag-
nostic criteria.
This study aimed to first-gather data on the prevalence 
of MetS in a subset of non-diabetic, pregnant Ango-
lan women; second-estimate the prevalence of MetS 
according to four diagnostic criteria: NCEP ATP III  [5], 
the Joint Interim Statement (JIS) definition  [6], and the 
modification of criteria for pregnancy proposed by Bar-
tha et  al. [10] and Chatzi et  al. [8, 9]; first-determine 
the level of agreement and disparity among these four 
criteria for the diagnosis of MetS and APO; and forth-




This mother–child, cross-sectional study examined a 
sample population of non-diabetic pregnant women 
from the public General Hospital of Huambo, Angola, to 
estimate the prevalence of metabolic syndrome (MetS) 
in pregnancy and its effects on APO. During the study 
period, which lasted from December 2014 to February 
2015, a total of 675 single, non-diabetic pregnant women 
with complete data were selected and enrolled in this 
study.
The study was conducted according to the tenets of the 
Declaration of Helsinki, and the protocol was approved 
by the Ethics Committee of the Faculty of Medicine, Ago-
stinho Neto University, Huambo, Angola.
All non-diabetic pregnant women in the maternity 
ward during this period were invited to participate 
and were included after an informed consent form was 
signed. Patients with established cardiovascular dis-
eases, thyroid dysfunction, excessive alcohol or other 
drug abuse, current or recent psychiatric treatment (upto 
4  months) during pregnancy and cesarean section were 
excluded. Eight nurses were trained on the structured 
guide for the survey. The interview guide was divided 
into three sections: socio-demographic characteristics, 
anthropometrics and biochemical evaluation.
On the test day, all consenting subjects provided infor-
mation for a structured questionnaire, underwent an 
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anthropometric examination and provided blood samples 
for biochemistry tests. Maternal characteristics such as age, 
parity, ethnicity, educational level, family income, smoking 
status, alcohol consumption and alimentary habits, weight 
and pre-pregnancy body mass index (BMI) were recorded.
All biochemical analyses were carried out within 2 h of 
blood sampling in the laboratory of the General Hospital 
of Huambo.
Pre-gestational BMI and waist circumference (WC) 
were obtained to quantify obesity. Body weight (kg) was 
measured to the nearest 0.1  kg using a previously cali-
brated mechanical scale (SECA GmbH & Co, Germany) 
with a maximum capacity of 200  kg. Standing body 
height (cm) was measured to the nearest 0.2  cm using 
a portable wall stadiometer (Seca, Germany). WC was 
measured in cm at the level of the navel using a flexible, 
non-distensible tape without exerting pressure on the 
tissues. Pre-gestational BMI was calculated as weight in 
kilograms divided by the square of the height (kg/m2). 
Three consecutive measurements of sitting blood pres-
sure at a minimum of 5-min intervals were recorded 
using Omrom® MX3 with an automated oscillometric 
Blood Pressure Monitor (O-HEM-742-E) (Matsusaka, 
Japan) [17].
After the participants had been sitting for at least 
30  min, were measures Systolic blood pressure (SBP, 
mmHg) and diastolic blood pressure (DBP, mmHg). 
Hypertension was defined as systolic blood pressure 
≥130 mmHg and diastolic blood pressure ≥85 mmHg.
In addition, venous blood samples were drawn from the 
forearm using standard techniques and were processed 
immediately using commercially available kits (BioSys-
tems SA, Costa Brava 30, Barcelona, Spain) to measure 
fasting plasma glucose (FPG, mg/dl), triglycerides (TG, 
mg/dl), total cholesterol (TC, mg/dl), low-density lipo-
protein cholesterol (LDL-C, mg/dl), and high-density 
lipoprotein cholesterol (HDL-C, mg/dl). All biochemical 
analyses were carried out within 2  h of blood sampling 
in the central laboratory of Huambo Hospital. This lab 
adheres to strict internal and external standards of qual-
ity control techniques.
Definition of metabolic syndrome in pregnancy
All participants were classified as either having or not 
having MetS according to four criteria, as indicated in 
Table  1, NCPE ATP III 2001 [5], JIS  and two modified 
definitions for pregnancy: Bartha et  al. [10] and Chatzi 
et al. [8, 9].
The definition of the four criteria was based on the 
presence of three or more of the five components 
(Table 1).
The ATP III  [5] components are WC >88  cm; SBP 
≥130 mmHg and/or DBP ≥85 mmHg and/or BP-lower-
ing treatment; fasting triglyceride levels ≥150 mg/dl and/
or treatment for hypertriglyceridemia; HDL-C <50  mg/
dl and/or treatment for dyslipidemia; and fasting glucose 
level ≥110 mg/dl and/or on antidiabetic medication.
The Joint Interim Statement (JIS) definition  [6] com-
ponents are WC >80 cm; SBP ≥130 mmHg and/or DBP 
≥85  mmHg and/or undergoing BP-lowering treatment; 
fasting triglyceride levels ≥150  mg/dl and/or treat-
ment for hypertriglyceridaemia; HDL-C <50 mg/dl and/
or treatment for dyslipidemia; and fasting glucose level 
≥100 mg/dl or on antidiabetic medication.
The Bartha et  al.  [10] modified criteria of NCEP 
APTIII characterize MetS by abdominal obesity, given 
WC >2 SD for gestational age in the first half of preg-
nancy or pre gestational BMI >30 kg/m2; triglycerides ≥2 
SD for gestational age; HDL-cholesterol <2 SD for gesta-
tional age; blood pressure ≥130/85 mm/Hg; and fasting 
glucose ≥105 mg/dl.
The Chatzi et al.  [8, 9] criteria, which modify HNLBI/
AHA and NECP ATP III, are as follows: pre gestational 
BMI >30  kg/m2; triglycerides ≥150  mg/dl; HDL choles-
terol <50 mg/dl; BP ≥130/85 mm/Hg; and fasting glucose 
≥100 mg/dl.
Adverse perinatal outcomes
Newborn data collection included birth weight, length, 
sex, gestational age at delivery, the first and fifth min-
utes’ perinatal morbidity and congenital malformations. 
Births were defined as pre-term if the gestational age was 
<37  weeks. The relation between the newborns’ weight 
Table 1 Criteria for clinical diagnosis of metabolic syndrome components according to four definitions
Components of MetS NCEP–ATP III [5] JIS MetS Criteria
[6]
NCEP–ATP III,  
Bartha et al. [10]  
modification
HNLBI/AHA, 
Chatzi et al.  [8, 9] 
modification
Prerequisite None None None None
No of other criteria ≥3 of: ≥3 of: ≥3 of: ≥3 of:
Obesity WC >88 cm WC ≥ 80 cm PG/BMI >30 kg/m2 PG/BMI >30 kg/m2
Hypertension (mm/Hg) ≥130/85 ≥130/85 ≥130/85 ≥130/85
Decreased HDL-C <50 mg/dl <50 mg/dl <2 SD (40 mg/dl) <50 mg/dl
Hypertriglyceridemia ≥150 mg/dl ≥150 mg/dl ≥2 SD/GA (270 mg/dl) ≥150 mg/dl
Increased fasting hyperglycemia ≥110 mg/dl ≥100 mg/dl ≥105 mg/dl ≥100 mg/dl
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and gestational age was defined according to Lubchenco’s 
criteria [18].
APO was diagnosed in the presence of any morbid-
ity factors, such as prematurity, a low Apgar score, mal-
formations, respiratory distress syndrome, jaundice, 
infections, large for gestational age (LGA), small for ges-
tational age (SGA) and macrosomia.
Statistical analysis
Data analyses were performed using the SAS 9.3 Foun-
dation for Microsoft® Windows® (Copyright © 2012, 
SAS Institute Inc., Cary, NC, USA). Data for categori-
cal variables are expressed as the number and per-
centage. Continuous variables are reported as the 
mean  ±  standard deviation and compared using the 
independent samples t test. Categorical variables were 
expressed as proportions and compared using the Chi 
square test or Fisher’s exact test if appropriate. The 
prevalence of MetS was determined according to the 
four criteria (NCEP ATP III 2001, the harmonized defi-
nition, the Bartha et  al. criteria that modified NCEP 
APT III and the Chatzi et  al. criteria that modified 
HNLBI/AHA). The kappa coefficient was calculated 
to evaluate the concordance among the definitions—
NCEP ATP III, the harmonized criteria, Bartha et  al. 
and Chatzi et al.—in detecting MetS and APO.
The agreement among the four definitions was deter-
mined by kappa statistics (κ). The level of agreement 
was considered poor for κ ≤ 0.20, fair for κ = 0.21–0.40, 
moderate for κ = 0.41–0.60, substantial for κ = 061–0.80 
and excellent for κ ≥ 0.80 [19].
The percentage of socio-demographic and obstetric 
variables, the prevalence of MetS, and the APO of non-
diabetic pregnant women with MetS were calculated and 
grouped as independent and dependent variables.
Independent variables: with or without MetS. Depend-
ent variables: with or without APOs. Comparisons 
between ‘with’ and ‘without’ MetS were made using a 
difference of proportions test for all criteria. Sensibility, 
specificity, and positive and negative predicted values 
were also calculated for all of the criteria used to diag-
nose of MetS and for APO. A p value <0.05 was consid-
ered statistically significant.
Results
A total of 675 non-diabetic pregnant women consented 
to participate in the survey. Full data sets were avail-
able from all participants and are the basis of this report. 
The mean values for the socio-demographic and various 
anthropometric, clinical and biochemical parameters of 
the study patients are presented in Table 2.
The mean age of the patients was 24 ± 6.7 years, and 
the mean gestational age was 39.2  weeks. In terms of 
educational background, 8.0 % were illiterate, 84.7 % had 
completed secondary education and 7.3 % had completed 
high school. One hundred forty-nine patients (22.1  %) 
were from urban areas, and 572 (84.7 %) were from rural 
areas. Only one patient was a smoker at the time of the 
study.
The major occupations of the patients were business 
(460, 68.1  %), student (141, 21.0  %) and public officials 
(74, 11.0  %). One hundred eighty-eight (27.8  %) were 
nulliparous.
Table 2 Frequency analysis of  socio-demographic 




 Black [n (%)] 675 (100)
 Other [n (%)] 0 (0)
Maternal age (years) 24.7 ± 6.7
Level of education
 Never studied [n (%)] 54 (8)
 Middle [n (%)] 572 (84.7)
 Higher education [n (%)] 49 (7.3)
Place of residence
 Urban [n (%)] 149 (22.1)
 Village [n (%)] 526 (77.9)
Occupation
 Students [n (%)] 141 (21.0)
 Business [n (%)] 460 (68.1)
 Public official [n (%)] 74 (11.0)
Smoking habit
 Non-smoker 674 (99.9)
 Current smoker (%) 1 (0.1)
Gestational age (weeks) 39.2 ± 1.6
Hypertension [n (%)] 370 (54.8)
Anti-hypertensive drugs (%) 44 (6.5)
Nulliparous 188 (27.8 %)
Glycemic level (mg/dl)
 ≥110 70 (10.4)
 ≥105 90 (13.3)
 ≥100 124 (18.4)
 <100 551 (81.6)
Fasting glycemia mean 83.7 ± 22.9
Obesity
 Mean waist circumference 93.6 ± 9.3
 BMI (kg/m2) 24.4 ± 4.2
Triglycerides (mg/dl) 149.3 ± 55.8
HDL-C (mg/dl) 70.9 ± 18.5
LDL-C (mg/dl) 116.9 ± 34.5
Total cholesterol (mg/dl) 193.2 ± 37.8
Adverse perinatal outcome (APO) 95 (14.1 %)
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In our study, the mean values of particular features of 
metabolic abnormalities characteristic of MetS among 
pregnant women are summarized in Table 2. Most of the 
women studied had normal blood glucose levels (551, 
81.6  %). Obesity was evaluated by two parameters: the 
mean pre-gestational BMI was 24.4 ± 4.2, and the mean 
WC at term was 93.6 ± 9.3 cm. The mean fasting plasma 
glucose was 83.7 ± 22.9 mg/dl, and the triglyceride, HDL-
C, LDL-C and total cholesterol means were 149.3 ± 55.8, 
70.9  ±  18.5, 116.9  ±  34.5, 193.2  ±  37.8, respectively. 
Hypertension was very common among pregnant women 
and was detected in 54.8 % of all patients; 6.5 % were tak-
ing medication for hypertension.
APOs were diagnosed in 14.1  % of the entire 
population.
The prevalence of MetS was estimated using NCEP 
ATP III, the Joint Interim Statement (JIS) definition, 
and the modified criteria for MetS in pregnancy by Bar-
tha et al. [10] and by Chatzi et al. [9]. The overall preva-
lence of MetS during pregnancy varied according to the 
four definitions: 36.6 % for the JIS, 29.2 % for the NCEP 
ATP III, 12.6  % for the Chatzi definition and 1.8  % for 
the Bartha definition. These results are shown in Table 3 
(p < 0.0001).
The prevalence of individual MetS components accord-
ing to the four criteria varied according to different crite-
ria, and the results are presented in Table 4.
Using the JIS definition, 36.0 % had high fasting blood 
glucose levels, 99.6  % had increased WC, 80.6  % had 
hypertriglyceridemia, 19.8 % had low HDL-C and 87.4 % 
presented hypertension.
Using the NCEP ATP III criteria, 22.3 % had increased 
fasting glucose levels, 95.9 %, had increased WC, 84.3 % 
had hypertriglyceridemia, 22.8 % had decreased HDL-C, 
and hypertension occurred in 90.9 %.
Using the Chatzi et  al. criteria, 47.1  % exhibited high 
fasting glucose levels, 47.1  % had a pre gestational 
BMI  >30, 91.8  % had hypertriglyceridemia, 37.6  % had 
low HDL-C and 92.9 % exhibited hypertension.
The Bartha et al. criteria detected the lowest percentage 
of MetS in pregnancy, with high fasting glucose levels in 
83.3 %, pre gestational BMI >30 in 91.7 %, hypertriglyc-
eridemia in 8.3 %, low HDL-C in 16.7 %, and all patients 
presenting hypertension.
The frequency of the number of MetS components in 
the NCEP ATP III, harmonized, Bartha and Chatzi cri-
teria are summarized in Table  5. The majority of non-
diabetic pregnant women had a cluster of one or two 
metabolic abnormalities in the four definitions used in 
this study.
Table  6 shows the comparison of socio-demographic 
and various anthropometric, clinical and biochemical 
parameters between groups with and without MetS com-
ponents included in the NCEP ATP III, JIS definition, 
and modified criteria for MetS in pregnancy by Bartha 
et al. and Chatzi et al.
Non-diabetic pregnant women with MetS were older 
according to three criteria (NCEP ATP III, the JIS defi-
nition and Bartha et  al.) and were overweight or obese 
(either with WC or BMI >30 before pregnancy) accord-
ing to all four criteria. They had high fasting blood glu-
cose levels, increased serum triglyceride levels, decreased 
serum HDL-C, increased hypertension prevalence and 
higher systolic and diastolic blood pressure (p < 0.05).
In the entire population, there were 129 APOs in 95 
newborns (14.1  %). The APOs were analyzed according 
to the four definitions that identified mothers with and 
without MetS (Table 7). The prevalence of newborns with 
APOs from non-diabetic mothers with and without MetS 
defined by the four definitions were similar. There was 
no statistically significant difference between any APO 
Table 3 Prevalence of metabolic syndrome according to four definitions and its components in pregnant women
* Differences of the test proporcções—p < 0.0001 (a, b, c and d)
Components of MetS NCEPT–ATP III [5]
N = 675
JIS MetS Criteria [6]
N = 675
NCEPT–ATP III Bartha [10] 
modification N = 675
NHLBI/AHA Chatzi [8, 9] 
modification
N = 675
Cut points N (%) Cut points N (%) Cut points N (%) Cut points N (%)
Fasting glycemia mean ≥110 mg/dl 70 (10.4) ≥100 mg/dl 124 (18.4) ≥105 mg/dl 90 (13.3) ≥100 mg/dl 124 (18.4)
Obesity
 BMI – – >30 kg/m2 75 (11.1) >30 kg/m2 75 (11.1)
 Waist circumference >88 cm 497 (73.6) ≥80 cm 657 (97.3) _ – –
Hypertriglyceridemia ≥150 mg/dl 293 (43.4) ≥150 mg/dl 293 (43.4) ≥270 mg/dl 15 (2.2) ≥150 mg/dl 293 (43.4)
Decreased HDL-C <50 mg/dl 53 (7.8) <50 mg/dl 53 (7.9) <40 mg/dl 17 (2.5) <50 mg/dl 53 (7.9)
Hypertension ≥130/85 mm/Hg 370 (54.8) ≥130/85 mm/Hg 370 (54.8) ≥ 130/85 mm/Hg 370 (54.8) ≥ 130/85 mm/Hg 370 (54.8)
MetS prevalence 197 (29.2) 247 (36.6) 12 (1.8) 85 (12.6)
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from mothers with and without MetS. Detailed APO data 
between the groups with and without MetS mothers are 
presented in Table 7.
The agreement and disagreement in the diagnosis of 
MetS among the four criteria is presented in Table 8. The 
agreement among these four definitions was ranked from 
excellent to poor. The agreement was excellent between 
NCEP ATP III–JIS definition [κ  =  0.8332 (0.7894–
0.8771), p < 0.001], considerable between Bartha–Chatzi 
[κ  =  0.2232 (0.1172–0.3292), p  <  0.001] and Chatzi–
JIS definition [κ  =  0.4036 (0.3389–0.4684), p  <  0.001], 
moderate between NCEP ATP III–Chatzi [κ  =  0.4320 
(0.3076–0.5064), p  <  0.001] and poor between Bartha–
ATP III [κ  =  0.0841 (0.0390–0.1293), p  <  0.001], and 
Bartha–JIS definition [κ  =  0.0608 (0.00275–0.0941), 
p < 0.001].
In terms of the diagnostic accuracy of MetS, the Bar-
tha et  al., NCEP ATP III and Chatzi et  al. definitions 
displayed the highest sensitivity (100  %) and negative 
predictive value (100 %), whereas NCEP ATPIII and the 
JIS definition had the highest specificity (100 %) and posi-
tive predictive value (100 %).
The agreement and disagreement among APO in the 
four definitions of MetS in non-diabetic pregnant women 
is presented in Table 9.
The agreement among these four definitions var-
ies from excellent to poor. The agreement was excel-
lent between NCEP ATP III–JIS definition [κ  =  0.86 
(0.76–0.9677), p 0.01]; considerable between Bar-
tha–Chatzi [κ  =  0.38 (0.11–0.65), p 0.0009]; moderate 
between NCEP ATP III–Chatzi [κ = 0.52 (0.34–0.71), p 
0.003] and Chatzi–JIS definition [κ  =  0.47 (0.30–0.64), 
p  <  0.001]; and slight between Bartha–NCEP ATP III 
[κ = 0.17 (0.02–0.33), p < 0.001] and Bartha–JIS defini-
tion [κ = 0.13 (0.01–0.26), p < 0.001].
The Bartha, NCEP ATP III, Chatzi and JIS definitions 
had the highest sensitivity (100  %) and negative predic-
tive value (100 %), whereas the NCEP ATPIII, JIS defini-
tion, and Bartha definitions had the highest specificity 
(100 %) and positive predictive value (100 %) for APO.
Discussion
This study described, for the first time, the global varia-
tion of MetS prevalence and its components in a sample 
of non-diabetic pregnant Angolan women, according to 
four definitions of MetS. Two classical definitions for 
MetS (NCEP ATP-III and the Joint Interim Statement-
JIS) and two other classical definitions modified for 
pregnant women (Bartha et  al. and Chatzi et  al.) were 
evaluated. There are some similarities among the compo-
nents of the four criteria: none had pre-requisites, three 
of the five components of MetS are required to establish 
a MetS diagnosis; and the level for hypertension diagno-
sis is the same. However, the cutoff for fasting glycemia 
varies from 100 to 110 mg/dl.
The assessment of obesity is the greatest difference 
between the four criteria: some use the classical WC, 
whereas others rely on pre gestational BMI.
Table 4 Prevalence of  individual metabolic syndrome abnormalities in  pregnant women with  metabolic syndrome 
according to four definitions
Components of MetS NCEPT–ATP III [5]
N = 197
JIS MetS Criteria [6]
N = 247
NCEPT–ATP III  
Bartha [10] modification 
N = 12
NHLBI/AHA Chatzi [8, 9] 
modification
N = 85
Increased fasting glycemia ≥110 mg/dl 44 (22.3) ≥100 mg/dl 89 (36.0) ≥105 mg/dl 10 (83.3) ≥100 mg/dl 40 (47.1)
Obesity
 BMI >30 kg/m2 11 (91.7) >30 kg/m2 40 (47.1)
 Waist circumference >88 cm 189 (95.9) ≥80 cm 246 (99.6) – –
Hypertriglyceridemia ≥150 mg/dl 166 (84.3) ≥150 mg/dl 199 (80.6) ≥270 mg/dl 1 (8.3) ≥150 mg/dl 78 (91.8)
Decreased HDL-C <50 mg/dl 45 (22.8) <50 mg/dl 49 (19.8) <40 mg/dl 2 (16.7) <50 mg/dl 32 (37.6)
Hypertension ≥130/85 mm/Hg 179 (90.9) ≥130/85 mm/Hg 216 (87.4) ≥130/85 mm/Hg 12 (100) ≥130/85 mm/Hg 79 (92.9)
Metabolic syndrome  % 29.2 (a) 36.6 (b) 1.8 (c) 12.6 (d)
Table 5 Frequency of individual components of metabolic 

















0 48 04 239 141
1 200 150 317 252
2 230 274 107 197
3 165 190 12 71
4 32 56 0 14
5 0 1 0 0
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Table 6 Comparison of  socio-demographic, clinical and  biochemical parameters in  pregnant women with  and with-
out metabolic syndrome according to four definitions
Variables NCEP ATP III [5] p value JIS MetS Criteria [6] p value








Mean age (year) 26.2 ± 6.8 24.0 ± 6.6 0.0002 25.6 ± 6.8 24.1 ± 6.7 0.0070
Level of education
 Never studied [n (%)] 21 (10.6) 33 (6.9) 0.1391 24 (9.7) 30 (7.0) 0.2706
 Middle 157 (79.7) 415 (86.8) 0.0162 203 (82.2) 369 (86.2) 0.1967
 Higher education 19 (9.6) 30 (6.3) 0.1706 20 (8.1) 29 (11.7) 0.6288
Place of residence
 Urban [n (%)] 50 (25.4) 99 (20.7) 0.2196 61 (24.7) 88 (20.6) 0.2495
 Village [n (%)] 147 (74.6) 379 (79.3) 0.2196 186 (75.3) 340 (79.4) 0.2495
Current smoker (%) 0 (0.0) 1 1.0 0 (0) 1 (0.2) 1.0
Mean body mass index – – – – – –
Mean waist circumference 97.4 ± 8.5 92.0 ± 9.1 <0.0001 95.6 ± 9.0 92.4 ± 9.3 <0.0001
Known diabetes mellitus (%) 00 00 – 00 00 –
Use of hypotensive drugs (%) 22 (11.1) 22 (4.6) 0.0029 23 (9.3) 21 (4.9) 0.0383
Fasting glycemia (mg/dl) 90.5 ± 29.1 80.9 ± 19.2 <0.0001 91.8 ± 27.4 79.1 ± 18.4 <0.0001
Hipertension 179 (90.9) 191 (39.9) <0.0001 216 (87.4) 154 (36.0) <0.0001
Systolic blood pressore 140.8 ± 18.5 124.4 ± 18.0 <0.0001 138.5 ± 18.7 123.8 ± 18.1 <0.0001
Diastolic blood presssure 90.7 ± 14.1 80.4 ± 13.6 <0.0001 89.3 ± 14.3 80.1 ± 13.6 <0.0001
Total cholesterol (mg/dl) [x ± s] 197.0 ± 42.9 191.4 ± 35.6 0.0810 196.2 ± 43.6 191.4 ± 33.9 0.1364
LDL-C (mg/dl) [x ± s] 122.0 ± 37.8 114.8 ± 32.8 0.020 120.2 ± 38.2 114.9 ± 31.9 0.0655
HDL-C(mg/dl) [x ± s] 64.5 ± 19.0 73.5 ± 17.7 <0.0001 65.8 ± 19.1 73.8 ± 17.5 <0.0001
Tryglicerides (mg/dl) [x ± s] 182.0 ± 60.2 135.0 ± 47.7 <0.0001 179.7 ± 59.5 131.7 ± 45.1 <0.0001
Variables NCEP ATP III [10] p value NHLBI/AHA [8, 9] p value




With N = 85 Without  
N = 590
Mean age (years) 28.7 ± 2 24.6 ± 6.7 0.0377 25.3 ± 6.9 24.6 ± 6.7 0.3217
Level of education
 Never studied [n (%)] 1 (8.3) 53 (7.9) 1.0 12 (14.1) 42 (7.1) 0.0444
 Middle 09 (75) 563 (84.9) 0.588 66 (77.6) 506 (85.8) 0.0744
 Higher education 02 (16.7) 47 (7.1) 0.4802 07(8.2) 42 (7.1) 0.8828
Place of residence
 Urban [n (%)] 04 (33.3) 145 (21.9) 0.55 28 (33.0) 121 (20.5) 0.0145
 Village [n (%)] 08 (66.7) 518 (78.1) 0.55 57 (67.0) 469 (79.5) 0.0145
Current smoker (%) 1.0 00 1.0 0 1 1.0
Mean body mass index 31.7 ± 4.1 24.2 ± 4.0 <0.0001 27.6 ± 5.0 23.9 ± 3.8 <0.0001
Mean waist circumference – – – – – –
Known diabetes mellitus (%) 00 00 – 00 00 –
Use of hypotensive drugs (%) 3 (25.0) 41 (6.2) 0.0426 11 (12.9) 33 (5.8) 0.0216
Fasting Glycemia (mg/dl) 126.7 ± 46.4 83.0 ± 21.6 0.0076 96.7 ± 34.1 81.9 ± 20.2 0.0002
Hipertension 12(100) 358 (54) 0.0039 79 ± 92.9 291 ± 49.3 <0.0001
Systolic Blood pressore 148.4 ± 20.6 128.8 ± 19.4 0.0006 140.4 ± 17.8 127.6 ± 19.3 <0.0001
Diastolic Blood presssure 96.3 ± 12.4 83.2 ± 14.5 0.00019 90.5 ± 15.6 82.4 ± 14.1 <0.0001
Total cholesterol (mg/dl) [x ± s] 174.5 ± 38.1 193.5 ± 37.7 0.043 115.1 ± 36.5 117.1 ± 34.2 0.6155
LDL-C (mg/dl) [x ± s] 107.0 ± 34.9 117.0 ± 34.4 0.316 187.8 ± 40.4 193.9 ± 37.4 0.1632
HDL-C (mg/dl) [x ± s] 58.0 ± 17.7 71.1 ± 18.5 0.0152 60.0 ± 21.3 72.4 ± 55.3 <0.0001
Tryglicérides (mg/dl) [x ± s] 126.7 ± 46.4 83.0 ± 21.6 0.0076 96.7 ± 34.1 81.9 ± 20.2 <0.0001
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Among non-diabetic, black, pregnant Angolan women, 
the highest prevalence rate was estimated by the Joint 
Interim Statement (JIS) definition (36.6  %), followed by 
NCEP ATPIII (29.2  %), Chatzi et  al. (12.6  %) and Bar-
tha et al. (1.8 %). Irrespective of the defining criteria, our 
study revealed a very high prevalence of MetS in non-dia-
betic, pregnant Angolan women. The overall prevalence 
(29.2  % by NCEP ATPIII criteria) in pregnant Angolan 
women is similar to that observed in the Nigerian general 
population (27.9 %), compared to 34.1 % in the USA, and 
is higher than the overall prevalence in Angola (17.6 %) 
and Canada [20].
These results may suggest significant implications for 
long-term cardiovascular complications, especially in 
populations of low- to mid-income countries such as 
Angola. Another explanation for this high prevalence of 
MetS could be the pregnancy itself, due to the increased 
abdominal circumference determined either by the 
gravid uterus or by maternal adaptations to pregnancy as 
metabolic and hematological changes occur. Many of the 
parameters involved in the definitions of MetS are part of 
the maternal adaptations to pregnancy [21].
The significantly different prevalence rates among the 
four definitions likely arise due to the different criteria 
used for obesity parameters—WC cut-off points and pre 
Table 8 Agreement and disagreement among metabolic syndrome definitions in pregnant women with metabolic syn-
drome and the diagnostic criteria according to each definition
Definitions Concordance Diagnostic accuracy (%)
k-value (95 % CI) p value Agreement Sensitivity Specificity PPV NPV
Bartha vs NCEP ATP III 0.0841 (0.0390–0.1293) <0.0001 Poor 100 72.1 6.1 100
NCEP ATP III vs Bartha 0.0841 (0.0390–0.1293) <0.0001 Poor 6.1 100 100 72.1
Bartha vs Chatzi 0.2232 (0.1172–0.3292) <0.0001 Considerable 100 88.9 14.1 100
Chatzi vs Bartha 0.2232 (0.1172–0.3292) <0.0001 Considerable 14.1 100 100 88.9
Bartha vs JIS 0.0608 (0.0275–0.0941) <0.0001 Poor 100 64.6 4.9 100
JIS vs Bartha 0.0608 (0.0275–0.0941) <0.0001 Poor 4.9 100 100 100
NECP ATP III vs JIS 0.8332 (0.7894–0.8771) <0.0001 Excellent 100 89.5 79.8 100
JIS vs NECP ATP III 0.8332 (0.7894–0.8771) <0.0001 Excellent 79.8 100 100 89.5
NCEP ATP III vs Chatzi 0.4320 (0.3076–0.5064) <0.0001 Moderate 38.1 97.9 88.2 79.3
Chatzi vs NCEP ATP III 0.4320 (0.3076–0.5064) <0.0001 Moderate 88.2 79.3 38.1 97.9
Chatzi vs JIS 0.4036 (0.3389–0.4684) <0.0001 Considerable 100 72.5 34.4 100
JIS vs Chatzi 0.4036 (0.3389–0.4684) <0.0001 Considerable 34.4 100 100 72.5
Table 9 Agreement and  disparity among  adverse pregnancy outcomes in  four definitions of  metabolic syndrome 
in pregnant women
Definitions Concordance Diagnostic accuracy (%)
k-value (95 % CI) p value Agreement Sensitivity Specificity PPV NPV
Bartha vs NCEP ATP III 0.1739 (0.0214–0.3264) <0.0001 Slight 100 71.4 13.3 100
NCEP ATP III vs Bartha 0.1739 (0.0214–0.3264) <0.0001 Slight 13.3 100 100 71.4
Bartha vs Chatzi 0.3798 (0.1095–0.6502) 0.0009 Considerable 100 87.9 26.7 100
Chatzi vs Bartha 0.3798 (0.1095–0.6502) 0.0009 Considerable 26.7 100 100 87.9
Bartha vs JIS 0.1344 (0.0121–0.2567) <0.0001 Slight 11.1 100 100 64.8
JIS vs Bartha 0.1344 (0.0121–0.2567) <0.0001 Slight 100 64.8 11.1 100
NCEP ATP III vs Chatzi 0.5215 (0.3364–0.7065) 0.0003 Moderate 93.3 80 46.7 98.5
Chatzi vs NCEP ATP III 0.5215 (0.3364–0.7065) 0.0003 Moderate 46.7 98.5 93.3 80
NECP ATP III vs JIS 0.8613 (0.7549–0.9677) 0.0143 Excellent 83.3 100 100 90.8
JIS vs NECP ATP III 0.8613 (0.7549–0.9677) 0.0143 Excellent 100 90.8 83.3 100
Chatzi vs JIS 0.4701 (0.3005–0.6397) <0.0001 Moderate 100 73.7 41.7 100
JIS vs Chatzi 0.4701 (0.3005–0.6397) <0.0001 Moderate 41.7 100 100 73.7
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gestational BMI. It is well established in the literature 
that different components of the criteria impact the MetS 
prevalence rates and may complicate the interpretation of 
epidemiological studies [22]. Another aspect that should 
be considered is the apparent similarity between the 
normal development of pregnancy to MetS, including a 
fraction of women showing increased blood glucose lev-
els, higher triglycerides and higher blood pressure levels. 
GDM and preeclampsia, which are considered features 
of MetS, are associated with exaggerated dyslipidemia, 
insulin and glucose metabolism abnormalities during and 
even after pregnancy. Women with MetS have a higher 
risk of developing preeclampsia than do those without 
MetS [23]. An increased prevalence of MetS was found 
to correspond with the worsening of glucose tolerance in 
Brazilian hyperglycemic mothers [7].
Pregnancy offers a unique window of time to inform 
women of the long-term implications of predictive fac-
tors such as anthropometric, biochemical and clinical 
parameters of MetS during pregnancy, which are not 
only transient metabolic abnormalities but may also be 
the first manifestation of a serious disease such as Type 2 
DM or CVD [7].
The high prevalence of MetS among our patients was 
surprising because they were low-risk, pregnant women, 
were at term and had vaginal delivery. This finding indi-
cates that in pregnant women, the criterion used to assess 
obesity by WC represents a confounding factor because 
the gravid uterus undermines the measurement. The WC 
has been proposed as a useful screening tool in many 
primary care settings, although in pregnant women, the 
WC is potentially problematic because the uterine size 
could interfere in this measurement. This has led to some 
confusion on the part of obstetricians regarding how to 
identify pregnant women with MetS. During pregnancy, 
the characterization of central obesity is difficult due to 
uterus enlargement. The suggested WC cut-off points to 
define MetS result from experts’ consensus and, in our 
view, justify additional clinical and epidemiological pro-
spective studies on pregnant women by using adverse 
perinatal outcomes as a dependent variable.
Recent guidelines released by the Joint Interim State-
ment (JIS)  [6] stressed the need to adopt ethnicity-spe-
cific values of WC to measure central obesity. For a given 
WC, Asians, blacks, and Caucasians showed different 
levels of intra-abdominal adiposity, thus putting the sub-
jects at different levels of risk for CVD and type2 DM [24, 
25].
However, these guidelines did not determine how to 
evaluate MetS during pregnancy, which cut-off points 
should be used to define abdominal obesity, the preva-
lence of MetS during pregnancy worldwide, and the 
impact of MetS both in pregnancy and in the perinatal 
period. The various diagnostic criteria have led to some 
confusion on the part of clinicians regarding how to iden-
tify pregnant women with MetS.
This issue suggests the need to reconsider the current 
cut-off points for WC to establish specific recommenda-
tions for pregnant women.
Although the two classical definitions of MetS were 
introduced in 2001 and 2005 and the consensus state-
ment was established in 2009 [2], disagreement remains 
regarding their use in clinical practice. This debate is 
caused by disparities in the results, as evidenced by the 
review by Oguoma, VM 2014 in Prevalence of cardio-
metabolic syndrome in Nigeria: a systematic review [20].
Conversely, the two definitions that have modified the 
classical consensus for MetS in pregnancy detected the 
lowest levels of MetS in non-diabetic, pregnant Angolan 
women [Chatzi et al. (12.6 %) and Bartha et al. (1.8 %)]. 
The definition proposed by Chatzi was based on an adap-
tation of the NHLB/AHA criteria, and obesity is defined 
as a pre gestational BMI >30 kg/m2. The authors analyzed 
the association between MetS characteristics before 
pregnancy and early in pregnancy and concluded that 
women with these MetS components were at a high risk 
of GDM development. The definition of obesity accord-
ing to the WHO criteria (BMI > 30 kg/m2) was used in 
four other studies evaluating MetS in pregnant women 
(Chatzi et  al. preterm; Bartha et  al.). These studies 
showed that MetS is not only directly responsible for the 
development of atherosclerotic cardiovascular disease 
but that it has additional impacts on human pregnancy, 
such as preterm delivery, low birth weight infants, and 
the development of diseases such as diabetes, preeclamp-
sia and hypertension.
Considering the apparent disagreement surrounding 
the evaluation of central obesity in the diagnosis of MetS, 
we found a substantial degree of agreement between the 
JIS definition and the NCEP ATPIII (0.83), which indi-
cates that the requirement of abdominal obesity did not 
generate significant discrepancies in the prevalence or 
the classification of the MetS; instead, the WC cut-off 
points did. Similar results were found in a large Chinese 
population, other Caucasian populations [27, 28], and in 
Luxembourg [28].
The definitions using pre gestational BMI in pregnancy 
exhibited considerable (0.22) agreement.
African pregnant women with MetS were older accord-
ing to three criteria (NCEP ATP III, the JIS definition and 
Bartha et al.) and more overweight or obese either with 
the WC or BMI  >30 before pregnancy variables based 
on all four criteria. They had higher fasting glycemia, 
increased serum triglyceride levels, decreased serum 
HDL-C, increased hypertension prevalence and higher 
systolic and diastolic blood pressure.
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Among the four definitions used, the JIS definition was 
found to be the most sensitive, and the NCEP ATPIII def-
inition was found to be most specific in identifying cases 
of MetS.
APO represents a group of maternal diseases and/or 
neonatal morbidity that interfere in perinatal results. It is 
well known that perinatal outcomes and quality of pre-
natal care are separate but related issues. Furthermore, 
perinatal outcomes depend in part upon the quality of 
care, the complexity of the case mix and maternal com-
plications. In a low-risk pregnant population from Africa, 
the prevalence of APO (14.1  %) was similar in mothers 
with and without MetS based on all four definitions. 
These results conflict with those found by Negrato et al. 
in a Brazilian cohort of hyperglycemic mothers who had 
or did not have MetS. The offspring of the hyperglycemic 
mothers with MetS presented significantly higher preva-
lences of Large for Gestational Age (LGA), overweight 
(ponderal index), Apgar scores (<7 at 1 min and 2 min) 
and any type of APOs.
Our study had a cross-sectional design and was con-
ducted among low-risk pregnant women from Huambo 
Hospital, which is located in the central highlands of 
Angola, a sub-Saharan area in Africa that does not neces-
sarily represent the entire pregnant population of Angola.
However, several points of strength do need to be high-
lighted. First is the high prevalence of MetS according 
to four definition criteria, considering the increased risk 
of future CVD diseases among non-diabetic, pregnant 
Angolan women. Second, this study describes the simi-
larities and differences among the classical definitions for 
MetS currently used outside pregnancy and those used 
in pregnancy to establish maternal and perinatal risks of 
MetS. This adverse maternal metabolic profile contrib-
utes to the epidemiological mapping of MetS in Angola 
and can serve as baseline data for low-risk pregnant 
women.
The completion of the JIS meeting to harmonize the 
criteria for the diagnosis of MetS emphasize that the 
new diagnosis elements, especially the WC, need to be 
addressed in the near future (JIS 2009). In our view, it is 
also necessary to establish correct and harmonized crite-
ria of MetS in pregnancy, which can be accomplished by 
longitudinal studies comparing pregnant women who are 
at low and high risk for MetS.
Our results show the importance of strategic efforts to 
improve prenatal care to avoid maternal and perinatal 
long-term consequences. This includes focusing on inter-
ventions such as whole family lifestyle modification with 
weight control, physical activity, and nutrition to control 
the MetS epidemic of the 21st century both during and 
after pregnancy.
Conclusions
The prevalence of metabolic syndrome in nondiabetic 
pregnant women considered criteria adapted pregnancy 
by Chatzi et al. (12.6 %) by Bartha et al. (1.8 %). Perina-
tal adverse outcome were higher in infants of mothers 
with metabolic syndrome, 41.7 % for criteria Bartha et al., 
and 25.9 % for the criteria Chatzi et al. This explains once 
again that women with metabolic syndrome have higher 
risk for newborns with perinatal adverse outcome, call-
ing attention to the need to prevent pre gestational syn-
drome, control it during pregnancy, especially in the first 
half.
We think that the criteria that best fits for the diagno-
sis of metabolic syndrome in pregnancy are the Bartha 
et  al., because women experience during pregnancy so 
forwarding components of metabolic syndrome. Bar-
tha et al. to consider these transformations, defined best 
cut-off points so that better predicts adverse perinatal 
outcomes.
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